IPO: TVAX Biomedical (TVAX)

TVAX Biomedical (TVAX), a biotech company focused on cancer cell vacination and T cell cancer treatment, plans to raise $20 million by offering 2,000,000 shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, TVAX Biomedical will command a market value of $80.93 million. TVAX Biomedical, which was founded in 2004, has not yet booked any operating revenues. The Lenexa, KS-based company plans to list on the NASDAQ under the symbol TVAX. Roth Capital is the lead underwriter on the deal. Please note: We are not issuing research on this IPO.